<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1287590b-abdf-470b-a611-dfb9bc93692a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ALOGLIPTIN TABLETS safely and effectively. See full prescribing information for ALOGLIPTIN TABLETS. <br/>
      <br/>Alogliptin Tablets, for oral use <br/>Initial U.S. Approval: 2013</title>
   <effectiveTime value="20250411"/>
   <setId root="b25f155a-1259-47c2-aa3b-7c1356e4c7f6"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="600093611" root="1.3.6.1.4.1.519.1"/>
            <name>Padagis Israel Pharmaceuticals Ltd</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9955c826-2c5f-471e-839a-392bbd4b5aaa"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250411"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="45802-087" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Alogliptin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Alogliptin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="6.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EEN99869SC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alogliptin Benzoate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JHC049LO86" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Alogliptin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Polyethylene Glycol 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric oxide Red</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Butyl Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="45802-087-65" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160408"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022271" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160408"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE">
                              <originalText>Light pink</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TAK;ALG;6;25</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="45802-103" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Alogliptin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Alogliptin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="12.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EEN99869SC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alogliptin Benzoate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JHC049LO86" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Alogliptin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Polyethylene Glycol 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric oxide Yellow</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Butyl Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="45802-103-65" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160408"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022271" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160408"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TAK;ALG;12;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="45802-150" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Alogliptin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Alogliptin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EEN99869SC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alogliptin Benzoate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JHC049LO86" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Alogliptin</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Polyethylene Glycol 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric oxide Red</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Shellac</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Butyl Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="45802-150-65" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160408"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022271" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160408"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RED" xsi:type="CE">
                              <originalText>Light red</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">TAK;ALG;25</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="b44bdf3a-f6c4-4d72-99c8-b569b1987bd0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</paragraph>
               </text>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="66860b28-7891-4a16-adba-2a5fadddb0e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="Bold">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Alogliptin tablet is not recommended for use in patients with type 1 diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="89be7f80-fc0e-4e2c-b42d-0aa28b8a7266"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage in patients with normal renal function or mild renal impairment is 25 mg orally once daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Can be taken with or without food. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Adjust dosage if moderate or severe renal impairment or end-stage renal disease (ESRD). (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                        <table width="100%">
                           <col width="33%" align="center" valign="top"/>
                           <col width="34%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th valign="bottom">Degree of Renal Impairment</th>
                                 <th valign="bottom">Creatinine Clearance<br/>(mL/min)</th>
                                 <th valign="bottom">Recommended Dosage</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td>Moderate</td>
                                 <td>≥30 to &lt;60</td>
                                 <td>12.5 mg once daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Severe/ESRD</td>
                                 <td>&lt;30</td>
                                 <td>6.25 mg once daily</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="f1191a1e-f983-4b6e-93b6-c5042a853939"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Recommended Dosage</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage of alogliptin tablets is 25 mg taken orally once daily. Do not spilt tablet.</item>
                           <item>Alogliptin tablets may be taken with or without food. <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                           </item>
                           <item>Instruct patients if a dose is missed, not to double their next dose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="f089edd1-6a70-4abd-a3b0-31c3ed8ee378"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Patients with Renal Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Assess renal function prior to initiation of alogliptin tablets and periodically thereafter <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</item>
                           <item>No dose adjustment of alogliptin tablets is necessary for patients with mild renal impairment (creatinine clearance [CrCl] ≥60 mL/min).</item>
                           <item>The dose of alogliptin tablets is 12.5 mg once daily for patients with moderate renal impairment (CrCl ≥30 to &lt;60 mL/min).</item>
                           <item>The dose of alogliptin tablets is 6.25 mg once daily for patients with severe renal impairment (CrCl ≥15 to &lt;30 mL/min) or with end-stage renal disease (ESRD) (CrCl &lt;15 mL/min or requiring hemodialysis). Alogliptin tablets may be administered without regard to the timing of dialysis. Alogliptin tablets have not been studied in patients undergoing peritoneal dialysis<content styleCode="italics"> [see<linkHtml href="#S8.6"> Use in Specific Populations (8.6)</linkHtml>,<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="1e6c4aa0-e36d-403a-b630-91c9fc6bb081"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>25 mg tablets are light red, oval, biconvex, film-coated, with "TAK ALG-25" printed on one side.</item>
                     <item>12.5 mg tablets are yellow, oval, biconvex, film-coated, with "TAK ALG-12.5" printed on one side.</item>
                     <item>6.25 mg tablets are light pink, oval, biconvex, film-coated, with "TAK ALG-6.25" printed on one side.</item>
                  </list>
               </text>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 25 mg, 12.5 mg and 6.25 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="97d10f16-031c-4fab-bbe3-7f8dfd80a42d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Alogliptin tablets is contraindicated in patients with a history of serious hypersensitivity to alogliptin or any of the excipients in Alogliptin tablets. Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of serious hypersensitivity to alogliptin or any of the excipients in Alogliptin tablets. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="9d6fd605-0be1-4be1-b015-d8aee17cdbe2"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue alogliptin tablets. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Heart failure: Consider the risks and benefits of alogliptin tablets prior to initiating treatment in patients at risk for heart failure. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of alogliptin tablets. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin tablets such as anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome. If hypersensitivity reactions occur, discontinue alogliptin tablets, treat promptly and monitor until signs and symptoms resolve. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt alogliptin tablets and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart alogliptin tablets if liver injury is confirmed and no alternative etiology can be found. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Bullous pemphigoid: There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue alogliptin tablets. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="9b1e0dc2-a679-483f-92e5-21e3d864a557"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Pancreatitis</title>
                     <text>
                        <paragraph>Acute pancreatitis has been reported in the postmarketing setting and in randomized clinical trials. In glycemic control trials in patients with type 2 diabetes mellitus, acute pancreatitis was reported in 6 (0.2%) patients treated with alogliptin tablets 25 mg and 2 (&lt;0.1%) patients treated with active comparators or placebo. In the EXAMINE trial (a cardiovascular outcomes trial of patients with type 2 diabetes mellitus and high cardiovascular (CV) risk), acute pancreatitis was reported in 10 (0.4%) of patients treated with alogliptin tablets and in 7 (0.3%) of patients treated with placebo.</paragraph>
                        <paragraph>It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using alogliptin tablets<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>After initiation of alogliptin tablets, patients should be observed for signs and symptoms of pancreatitis. If pancreatitis is suspected, alogliptin tablets should promptly be discontinued and appropriate management should be initiated.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="05ac5e30-87cf-4bfd-987d-7f85d26a955b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Heart Failure</title>
                     <text>
                        <paragraph>In the EXAMINE trial which enrolled patients with type 2 diabetes mellitus and recent acute coronary syndrome, 106 (3.9%) of patients treated with alogliptin tablets and 89 (3.3%) of patients treated with placebo were hospitalized for congestive heart failure.</paragraph>
                        <paragraph>Consider the risks and benefits of alogliptin tablets prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Patients should be advised of the characteristic symptoms of heart failure and should be instructed to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of alogliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="5e5c4559-7bc8-4c5f-bbde-3b24def10b84"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>There have been postmarketing reports of serious hypersensitivity reactions in patients treated with alogliptin tablets <content styleCode="italics"> [see<linkHtml href="#S6.2"> Adverse Reactions (6.2)</linkHtml>]</content>. These reactions include anaphylaxis, angioedema, and severe cutaneous adverse reactions, including Stevens-Johnson syndrome. If a serious hypersensitivity reaction is suspected, discontinue alogliptin tablets, assess for other potential causes for the event and institute alternative treatment for diabetes mellitus. Use caution in patients with a history of angioedema with another dipeptidyl peptidase-4 (DPP-4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with alogliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="28f6c17d-09e5-403d-a181-2405bcb86d9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Hepatic Effects</title>
                     <text>
                        <paragraph>There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking alogliptin tablets, although some of the reports contain insufficient information necessary to establish the probable cause<content styleCode="italics"> [see<linkHtml href="#S6.2"> Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>In glycemic control trials in patients with type 2 diabetes mellitus, serum alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (ULN) were reported in 1.3% of patients treated with alogliptin tablets 25 mg and 1.7% of patients treated with active comparators or placebo. In the EXAMINE trial (a cardiovascular outcomes trial of patients with type 2 diabetes mellitus and high cardiovascular (CV) risk), increases in serum alanine aminotransferase three times the upper limit of the reference range occurred in 2.4% of patients treated with alogliptin tablets and in 1.8% of patients treated with placebo.</paragraph>
                        <paragraph>Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have clinically significant liver enzyme elevations and if abnormal liver tests persist or worsen, alogliptin tablets should be interrupted and investigation done to establish the probable cause. Alogliptin tablets should not be restarted in these patients without another explanation for the liver test abnormalities.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="deedf760-efa5-4a1a-be6e-3d8755fa1814"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</title>
                     <text>
                        <paragraph>Insulin and insulin secretagogues, such as sulfonylureas, are known to cause hypoglycemia. Therefore, a lower dosage of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with alogliptin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="1a6ff968-f836-4431-967c-9316c5151234"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Severe and Disabling Arthralgia</title>
                     <text>
                        <paragraph>There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="43c6cbc0-96b2-434c-a3d4-8282e71f8121"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Bullous Pemphigoid</title>
                     <text>
                        <paragraph>Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving alogliptin tablets. If bullous pemphigoid is suspected, alogliptin tablets should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="956a355e-fba6-4a54-bafd-7c6fa5959219"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described below or elsewhere in the prescribing information:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Pancreatitis<content styleCode="italics"> [see<linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Heart Failure<content styleCode="italics"> [see<linkHtml href="#S5.2"> Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity Reactions<content styleCode="italics"> [see<linkHtml href="#S5.3"> Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Hepatic Effects<content styleCode="italics"> [see<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Severe and Disabling Arthralgia<content styleCode="italics"> [see<linkHtml href="#S5.6"> Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Bullous Pemphigoid<content styleCode="italics"> [see<linkHtml href="#S5.7"> Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250411"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt;4%) are nasopharyngitis, headache and upper respiratory tract infection. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or <content styleCode="underline">
                                 <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="337bebf3-5502-4d47-b6b3-59a9fd02fe6b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>A total of 14,778 patients with type 2 diabetes mellitus participated in 14 randomized, double-blind, controlled clinical trials of whom 9,052 subjects were treated with alogliptin tablets, 3,469 subjects were treated with placebo and 2,257 were treated with an active comparator. The racial distribution of patients exposed to trial medication was 71% White, 17% Asian, 6% Black or African American, 2% American Indian or Alaska Native, 0% Native Hawaiian/Other Pacific Islander and 5% Multiracial or other racial groups. The ethnic distribution was 30% Hispanic or Latino and 70% was not Hispanic or Latino. The mean duration of diabetes mellitus was seven years, the mean body mass index (BMI) was 31 kg/m<sup>2 </sup>(49% of patients had a BMI ≥30 kg/m<sup>2</sup>), and the mean age was 58 years (26% of patients ≥65 years of age). The mean exposure to alogliptin tablets was 49 weeks with 3,348 subjects treated for more than one year.</paragraph>
                        <paragraph>In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse reactions was 73% in patients treated with alogliptin tablets 25 mg compared to 75% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse reactions was 6.8% with alogliptin tablets 25 mg compared to 8.4% with placebo or 6.2% with active comparator.</paragraph>
                        <paragraph>Adverse reactions reported in ≥4% of adult patients treated with alogliptin tablets 25 mg and more frequently than in patients who received placebo are summarized in<content styleCode="italics"> Table 1</content>.</paragraph>
                        <table ID="table1" width="75%">
                           <caption>Table 1. Adverse Reactions Reported in ≥4% of Adult Patients with Type 2 Diabetes Mellitus Treated with Alogliptin Tablets 25 mg and More Frequently Than in Patients Given Placebo in Pooled Trials</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="17%" align="center" valign="top"/>
                           <col width="17%" align="center" valign="top"/>
                           <col width="16%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th colspan="3" styleCode="Rrule">Number of Patients (%)</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Alogliptin Tablets<br/>25 mg</th>
                                 <th styleCode="Rrule">Placebo</th>
                                 <th styleCode="Rrule">Active Comparator</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">N=6447</td>
                                 <td styleCode="Rrule">N=3469</td>
                                 <td styleCode="Rrule">N=2257</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Nasopharyngitis</td>
                                 <td styleCode="Rrule">309 (5)</td>
                                 <td styleCode="Rrule">152 (4)</td>
                                 <td styleCode="Rrule">113 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Upper Respiratory Tract Infection</td>
                                 <td styleCode="Rrule">287 (4)</td>
                                 <td styleCode="Rrule">121 (4)</td>
                                 <td styleCode="Rrule">113 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Headache</td>
                                 <td styleCode="Rrule">278 (4)</td>
                                 <td styleCode="Rrule">101 (3)</td>
                                 <td styleCode="Rrule">121 (5)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="f31f372a-f931-4461-bf89-dc3ba2568b11"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold">Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.</paragraph>
                              <paragraph>In the monotherapy trial, the incidence of hypoglycemia was 1.5% in patients treated with alogliptin tablets compared to 1.6% with placebo. The use of alogliptin tablets as add-on therapy to glyburide or insulin did not increase the incidence of hypoglycemia compared to placebo. In a monotherapy trial comparing alogliptin tablets to a sulfonylurea in elderly patients, the incidence of hypoglycemia was 5.4% with alogliptin tablets compared to 26% with glipizide<content styleCode="italics"> (Table 2)</content>.</paragraph>
                              <table ID="table2" width="100%">
                                 <caption>Table 2. Incidence and Rate of Hypoglycemia<footnote ID="t2f1">Adverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population.</footnote> in Placebo and Active-Controlled Trials in Adults with Type 2 Diabetes Mellitus when Alogliptin Tablets Were Used as Add-On Therapy to Glyburide, Insulin, Metformin, Pioglitazone or Compared to Glipizide or Metformin</caption>
                                 <col width="33%" align="left" valign="middle"/>
                                 <col width="34%" align="center" valign="middle"/>
                                 <col width="33%" align="center" valign="middle"/>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Add-On to Glyburide<br/>(26 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Placebo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=198</td>
                                       <td styleCode="Rrule">N=99</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">19 (10)</td>
                                       <td styleCode="Rrule">11 (11)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnote ID="t2f2">Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level or loss of consciousness or seizure.</footnote>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1 (1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Add-On to Insulin (± Metformin)<br/>(26 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="Bold">Placebo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=129</td>
                                       <td styleCode="Rrule">N=129</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">35 (27)</td>
                                       <td styleCode="Rrule">31 (24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">1 (1)</td>
                                       <td styleCode="Rrule">2 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Add-On to Metformin<br/>(26 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule" valign="top">
                                          <content styleCode="Bold">Placebo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=207</td>
                                       <td styleCode="Rrule">N=104</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3 (3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Add-On to Pioglitazone<br/>(± Metformin or Sulfonylurea)<br/>(26 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Placebo</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=199</td>
                                       <td styleCode="Rrule">N=97</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">14 (7)</td>
                                       <td styleCode="Rrule">5 (5)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1 (1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Compared to Glipizide<br/>(52 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Glipizide</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=222</td>
                                       <td styleCode="Rrule">N=219</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">12 (5)</td>
                                       <td styleCode="Rrule">57 (26)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3 (1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Compared to Metformin<br/>(26 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Metformin 500 mg<br/>twice daily</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=112</td>
                                       <td styleCode="Rrule">N=109</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">2 (2)</td>
                                       <td styleCode="Rrule">2 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Add-On to Metformin Compared to Glipizide<br/>(52 Weeks)</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Alogliptin Tablets 25 mg</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="Bold">Glipizide</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule"/>
                                       <td styleCode="Rrule">N=877</td>
                                       <td styleCode="Rrule">N=869</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Overall (%)</td>
                                       <td styleCode="Rrule">12 (1)</td>
                                       <td styleCode="Rrule">207 (24)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Severe (%)<footnoteRef IDREF="t2f2"/>
                                       </td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">4 (1)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the EXAMINE trial, the incidence of investigator reported hypoglycemia was 6.7% in patients receiving alogliptin tablets and 6.5% in patients receiving placebo. Serious adverse reactions of hypoglycemia were reported in 0.8% of patients treated with alogliptin tablets and in 0.6% of patients treated with placebo.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e2dec456-7d33-4076-8814-b68ab9b67514"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold">Renal Impairment</content>
                              </paragraph>
                              <paragraph>In glycemic control trials in patients with type 2 diabetes mellitus, 3.4% of patients treated with alogliptin tablets and 1.3% of patients treated with placebo had renal function adverse reactions. The most commonly reported adverse reactions were renal impairment (0.5% for alogliptin tablets and 0.1% for active comparators or placebo), decreased creatinine clearance (1.6% for alogliptin tablets and 0.5% for active comparators or placebo) and increased blood creatinine (0.5% for alogliptin tablets and 0.3% for active comparators or placebo)<content styleCode="italics"> [see<linkHtml href="#S8.6"> Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>In the EXAMINE trial of high CV risk type 2 diabetes mellitus patients, 23% of patients treated with alogliptin tablets and 21% of patients treated with placebo had an investigator reported renal impairment adverse reaction. The most commonly reported adverse reactions were renal impairment (7.7% for alogliptin tablets and 6.7% for placebo), decreased glomerular filtration rate (4.9% for alogliptin tablets and 4.3% for placebo) and decreased renal clearance (2.2% for alogliptin tablets and 1.8% for placebo). Laboratory measures of renal function were also assessed. Estimated glomerular filtration rate decreased by 25% or more in 21.1% of patients treated with alogliptin tablets and 18.7% of patients treated with placebo. Worsening of chronic kidney disease stage was seen in 16.8% of patients treated with alogliptin tablets and in 15.5% of patients treated with placebo. </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="b7c562d0-b428-4765-af55-1f40db84efe3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during the postmarketing use of alogliptin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> acute pancreatitis, diarrhea, constipation, nausea, ileus</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders:</content> fulminant hepatic failure</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> hypersensitivity reactions including anaphylaxis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> hepatic enzyme elevations</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> severe and disabling arthralgia, rhabdomyolysis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content> tubulointerstitial nephritis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> angioedema, rash, urticaria and severe cutaneous adverse reactions including Stevens-Johnson syndrome, bullous pemphigoid</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="dc6d0781-b7dd-47db-abf5-405e9258cb87"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250411"/>
               <component>
                  <section ID="S7.1">
                     <id root="5279fbf8-6008-4527-bb93-652458059103"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Insulin Secretagogues and Insulin</title>
                     <text>
                        <paragraph>Insulin and insulin secretagogues are known to cause hypoglycemia. Coadministration of alogliptin tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue and insulin to reduce the risk of hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.
                              </paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="5564878b-5172-4024-a50e-43cada6be03b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250411"/>
               <component>
                  <section ID="S8.1">
                     <id root="7e693d93-4155-418d-9dba-6a1f07d27c00"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="3ab2183f-7a0d-4cac-b0c4-dae4638b12b5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited data with alogliptin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy<content styleCode="italics"> [see<linkHtml href="#clincon"> Clinical Considerations</linkHtml>].</content>
                              </paragraph>
                              <paragraph>No adverse developmental effects were observed when alogliptin was administered to pregnant rats and rabbits during organogenesis at exposures 180- and 149-times the 25 mg clinical dose, respectively, based on plasma drug exposure (AUC)<content styleCode="italics"> [see<linkHtml href="#data"> Data</linkHtml>]</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes mellitus with a HbA1c &gt;7 and has been reported to be as high as 20-25% in women with HbA1c &gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3951bae0-d0b2-4f18-a971-8ace52d42c7b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold" ID="clincon">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                           <component>
                              <section>
                                 <id root="44773e9f-6266-4471-a2f1-297b3d8bbf8d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Poorly controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="05a952d4-41b7-4518-aee3-226d5a0bd6bf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold" ID="data">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                           <component>
                              <section>
                                 <id root="68e87eec-38a6-436d-aa27-1461fc8735ff"/>
                                 <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="Bold">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Alogliptin administered to pregnant rabbits and rats during the period of organogenesis did not cause adverse developmental effects at doses of up to 200 mg/kg and 500 mg/kg, or 149 times and 180 times, the 25 mg clinical dose, respectively, based on plasma drug exposure (AUC). Placental transfer of alogliptin into the fetus was observed following oral dosing to pregnant rats.</paragraph>
                                    <paragraph>No adverse developmental outcomes were observed in offspring when alogliptin was administered to pregnant rats during gestation and lactation at doses up to 250 mg/kg (~ 95 times the 25 mg clinical dose, based on AUC).</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="e8e67f34-3d58-4388-8483-1d008df03364"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="83da68ef-2b2c-4810-b7ec-9dc5eed8d37f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of alogliptin in human milk, the effects on the breastfed infant, or the effects on milk production. Alogliptin is present in rat milk: however, due to species specific differences in lactation physiology, animal lactation data may not reliably predict levels in human milk<content styleCode="italics">. </content>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for alogliptin tablets and any potential adverse effects on the breastfed infant from alogliptin tablets or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="7c56589b-3c0c-4a72-a2d2-5e57d3965f36"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of alogliptin tablets have not been established in pediatric patients.</paragraph>
                        <paragraph>Effectiveness of alogliptin tablets was not demonstrated in a 52 week, randomized, double-blind, placebo-controlled trial (NCT02856113) in 151 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes mellitus.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="aef302ab-6185-4712-aa2e-8995658e3222"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of patients (N=9052) in clinical safety and efficacy trials treated with alogliptin tablets, 2,257 (24.9%) patients were 65 years and older and 386 (4.3%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="c837582e-f996-431d-930f-193158cce04f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>A total of 602 adult patients with moderate renal impairment (eGFR ≥30 and &lt;60 mL/min/1.73 m<sup>2</sup>) and 4 patients with severe renal impairment/end-stage renal disease (eGFR &lt;30 mL/min/1.73 m<sup>2 </sup>or &lt;15 mL/min/1.73 m<sup>2</sup>, respectively) at baseline were treated with alogliptin tablets in clinical trials in patients with type 2 diabetes mellitus.</paragraph>
                        <paragraph>In the EXAMINE trial of high CV risk type 2 diabetes mellitus patients, 694 patients had moderate renal impairment and 78 patients had severe renal impairment or end-stage renal disease at baseline.</paragraph>
                        <paragraph>The recommended dose is 12.5 mg once daily in patients with moderate renal impairment and 6.25 mg once daily in patients with severe renal impairment, as well as in patients with ESRD requiring dialysis. Alogliptin tablets may be administered without regard to the timing of the dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="150604aa-b7a5-4d70-b1e3-bc41b41b575b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7	Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustments are required in patients with mild to moderate hepatic impairment (Child-Pugh Grade A and B) <content styleCode="italics"> [see<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>. Alogliptin tablets have not been studied in patients with severe hepatic impairment (Child-Pugh Grade C). Use caution when administering alogliptin tablets to patients with liver disease<content styleCode="italics"> [see<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="585290c0-85c8-4a53-8176-1618baf48fcc"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of an overdose, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract.</paragraph>
                  <paragraph>Alogliptin is minimally dialyzable; over a three-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an overdose situation. It is not known if alogliptin tablets are dialyzable by peritoneal dialysis.</paragraph>
                  <paragraph>In the event of an overdose, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250411"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="5de30ae5-4346-4dac-affc-0c8d064c629d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Alogliptin tablets contain the active ingredient alogliptin, which is a selective, orally bioavailable inhibitor of the enzymatic activity of DPP-4.</paragraph>
                  <paragraph>Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3<content styleCode="italics">R</content>)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2<content styleCode="italics">H</content>)-yl}methyl)benzonitrile monobenzoate. It has a molecular formula of C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>∙C<sub>7</sub>H<sub>6</sub>O<sub>2 </sub>and a molecular weight of 461.51 daltons. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Alogliptin benzoate is a white to off-white crystalline powder containing one asymmetric carbon in the aminopiperidine moiety. It is soluble in dimethylsulfoxide, sparingly soluble in water and methanol, slightly soluble in ethanol and very slightly soluble in octanol and isopropyl acetate.</paragraph>
                  <paragraph>Each alogliptin tablet contains 34 mg, 17 mg or 8.5 mg alogliptin benzoate, which is equivalent to 25 mg, 12.5 mg or 6.25 mg, respectively, of alogliptin and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, mannitol, and microcrystalline cellulose. In addition, the film coating contains the following inactive ingredients: ferric oxide (red or yellow), hypromellose, polyethylene glycol, and titanium dioxide and is marked with printing ink (Gray F1).</paragraph>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alogliptin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="71bcc4ab-a3cf-47f6-b0d6-526f8dc73d29"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250411"/>
               <component>
                  <section ID="S12.1">
                     <id root="8dc42f18-f68c-40fc-83f5-5a8dd6ad5fcc"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes mellitus, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. Alogliptin selectively binds to and inhibits DPP-4 but not DPP-8 or DPP-9 activity<content styleCode="italics"> in vitro </content>at concentrations approximating therapeutic exposures.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="3ba1c19e-b592-48d4-bf03-a6a1cae959b5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dose-Response Relationships</content>
                        </paragraph>
                        <paragraph>Single-dose administration of alogliptin tablets to healthy subjects resulted in a peak inhibition of DPP-4 within two to three hours after dosing. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Peak and total exposure over 24 hours to active GLP-1 were three- to four-fold greater with alogliptin tablets (at doses of 25 to 200 mg) than placebo. In a 16 week, double-blind, placebo-controlled study, alogliptin tablets 25 mg demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an eight hour period following a standardized meal. It is unclear how these findings relate to changes in overall glycemic control in patients with type 2 diabetes mellitus. In this study, alogliptin tablets 25 mg demonstrated decreases in two hour postprandial glucose compared to placebo (-30 mg/dL versus 17 mg/dL, respectively).</paragraph>
                        <paragraph>Multiple-dose administration of alogliptin to patients with type 2 diabetes mellitus also resulted in a peak inhibition of DPP-4 within one to two hours and exceeded 93% across all doses (25 mg, 100 mg and 400 mg) after a single dose and after 14 days of once-daily dosing. At these doses of alogliptin tablets, inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="7fb96a15-eb25-4060-ae2c-b825b32fca15"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>In a randomized, placebo-controlled, four-arm, parallel-group study, 257 subjects were administered either alogliptin 50 mg, alogliptin 400 mg, moxifloxacin 400 mg or placebo once daily for a total of seven days. No increase in corrected QT (QTc) was observed with either dose of alogliptin. At the 400 mg dose, peak alogliptin plasma concentrations were 19-fold higher than the peak concentrations following the maximum recommended clinical dose of 25 mg.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="ee5094e2-c639-4629-ab4c-600383f239a6"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of alogliptin tablets has been studied in healthy subjects and in patients with type 2 diabetes mellitus. The pharmacokinetics of alogliptin tablets were similar in healthy subjects and in patients with type 2 diabetes mellitus.</paragraph>
                        <paragraph>After multiple-dose administration up to 400 mg for 14 days in patients with type 2 diabetes mellitus, accumulation of alogliptin was minimal with an increase in total [e.g., area under the plasma concentration curve (AUC)] and peak (i.e., C<sub>max</sub>) alogliptin exposures of 34% and 9%, respectively. Total and peak exposure to alogliptin increased proportionally across single doses and multiple doses of alogliptin ranging from 25 mg to 400 mg. The intersubject coefficient of variation for alogliptin AUC was 17%.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="728528c1-1413-4564-aebd-83d3133762b2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Absorption</content>
                              </paragraph>
                              <paragraph>After administration of single, oral doses up to 800 mg in healthy subjects, the peak plasma alogliptin concentration (median T<sub>max</sub>) occurred one to two hours after dosing. The absolute bioavailability of alogliptin tablets is approximately 100%.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ccc19f76-3166-4d3a-805f-59d914e1c659"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Effect of Food</content>
                              </paragraph>
                              <paragraph>Administration of alogliptin tablets with a high-fat meal results in no significant change in total and peak exposure to alogliptin.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ee313f39-a5a2-4578-b26b-f702053eb0c9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Distribution</content>
                              </paragraph>
                              <paragraph>Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.</paragraph>
                              <paragraph>Alogliptin is 20% bound to plasma proteins.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4aa2624e-2d2f-460c-ab78-5c5fea38469e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Underline">Elimination</content>
                              </paragraph>
                              <paragraph>Alogliptin tablets was eliminated with a mean terminal half-life (t<sub>1/2</sub>) of approximately 21 hours. The renal clearance of alogliptin (9.6 L/hr) indicates some active renal tubular secretion and systemic clearance was 14.0 L/hr.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5e326aa8-0f0d-450b-a78c-2aed2cb67de2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>Alogliptin does not undergo extensive metabolism and 60% to 71% of the dose is excreted as unchanged drug in the urine.</paragraph>
                              <paragraph>Two minor metabolites were detected following administration of an oral dose of [<sup>14</sup>C] alogliptin, <content styleCode="italics">N</content>-demethylated, M-I (less than 1% of the parent compound), and<content styleCode="italics"> N</content>-acetylated alogliptin, M-II (less than 6% of the parent compound). M-I is an active metabolite and is an inhibitor of DPP-4 similar to the parent molecule; M-II does not display any inhibitory activity toward DPP-4 or other DPP-related enzymes.<content styleCode="italics"> In vitro </content>data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</paragraph>
                              <paragraph>Alogliptin exists predominantly as the (<content styleCode="italics">R</content>)-enantiomer (more than 99%) and undergoes little or no chiral conversion<content styleCode="italics"> in vivo </content>to the (<content styleCode="italics">S</content>)-enantiomer. The (<content styleCode="italics">S</content>)-enantiomer is not detectable at the 25 mg dose.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4b00e454-6c07-485f-aad4-ea106b363e4c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>The primary route of elimination of [<sup>14</sup>C] alogliptin-derived radioactivity occurs via renal excretion (76%) with 13% recovered in the feces, achieving a total recovery of 89% of the administered radioactive dose.</paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b5f4f210-091e-4013-8f71-a21eec1e6821"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                           <component>
                              <section>
                                 <id root="02756799-fc8b-4d22-bfee-ce8a508a4280"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>Age (18 to 80 years old) did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="b43cd6af-64dd-4fa0-be01-b02584ef69f5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Male and Female Patients</content>
                                    </paragraph>
                                    <paragraph>Gender did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c938a58b-0385-4be5-9097-ea3121dd4ef1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Racial or Ethnic Groups</content>
                                    </paragraph>
                                    <paragraph>Race (White, Black or African American and Asian) did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="90841288-09d3-4069-8e8b-0ffedcee65c5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of alogliptin 50 mg in patients with chronic renal impairment compared with healthy subjects.</paragraph>
                                    <paragraph>In patients with mild renal impairment (creatinine clearance [CrCl] ≥60 to &lt;90 mL/min), an approximate 1.2-fold increase in plasma AUC of alogliptin was observed.</paragraph>
                                    <paragraph>In patients with moderate renal impairment (CrCl ≥30 to &lt;60 mL/min), an approximate two-fold increase in plasma AUC of alogliptin was observed.</paragraph>
                                    <paragraph>In patients with severe renal impairment (CrCl ≥15 to &lt;30 mL/min) and end-stage renal disease (ESRD) (CrCl &lt;15 mL/min or requiring dialysis), an approximate three- and four-fold increase in plasma AUC of alogliptin were observed, respectively. Dialysis removed approximately 7% of the drug during a three-hour dialysis session. <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="dbedac88-3c4c-47a8-a401-aeb005b33169"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment (Child-Pugh Grade B) compared to healthy subjects. The magnitude of these reductions is not considered to be clinically meaningful. Patients with severe hepatic impairment (Child-Pugh Grade C) have not been studied <content styleCode="italics"> [see<linkHtml href="#S8.7"> Use in Specific Populations (8.7)</linkHtml>,<linkHtml href="#S5.4"> Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="180df6fa-b473-4088-a84c-d719af74fd6c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Clinical Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250411"/>
                           <component>
                              <section>
                                 <id root="2d3274d0-ecd1-464b-a27f-4080fdc4b1ce"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="Bold underline">Effects of Alogliptin on the Pharmacokinetics of Other Drugs</content>
                                    </paragraph>
                                    <paragraph>In clinical studies, alogliptin did not meaningfully increase the systemic exposure to the following drugs that are metabolized by CYP isozymes or excreted unchanged in urine<content styleCode="italics"> (Figure 1)</content>. No dose adjustment of alogliptin tablets is recommended based on results of the described pharmacokinetic studies.</paragraph>
                                    <paragraph>
                                       <content styleCode="Bold">Figure 1. Effect of Alogliptin on the Pharmacokinetic Exposure to Other Drugs</content>
                                    </paragraph>
                                    <renderMultiMedia referencedObject="MM2"/>
                                    <paragraph>*Warfarin was given once daily at a stable dose in the range of 1 mg to 10 mg. Alogliptin had no significant effect on the prothrombin time (PT) or International Normalized Ratio (INR).</paragraph>
                                    <paragraph>**Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate) and fexofenadine (P-gp substrate) were administered as a cocktail.</paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                                 <component>
                                    <observationMedia ID="MM2">
                                       <text>Figure 1</text>
                                       <value xsi:type="ED" mediaType="image/jpeg">
                                          <reference value="alogliptin-02.jpg"/>
                                       </value>
                                    </observationMedia>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="5a384830-b396-45bc-a423-9c61d1cf3272"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="Bold underline">Effects of Other Drugs on the Pharmacokinetics of Alogliptin</content>
                                    </paragraph>
                                    <paragraph>There are no clinically meaningful changes in the pharmacokinetics of alogliptin when alogliptin tablets are administered concomitantly with the drugs described below<content styleCode="italics"> (Figure 2)</content>.</paragraph>
                                    <paragraph>
                                       <content styleCode="Bold">Figure 2. Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin</content>
                                    </paragraph>
                                    <paragraph>
                                       <renderMultiMedia referencedObject="MM3"/>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250411"/>
                                 <component>
                                    <section>
                                       <id root="9a7c3bbe-ca71-481b-9e91-029f25f59b09"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">In Vitro Studies</content>
                                          </paragraph>
                                          <paragraph>
                                             <content styleCode="underline">Effect of Alogliptin on CYP Enzymes</content>
                                          </paragraph>
                                          <paragraph>Alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.</paragraph>
                                       </text>
                                       <effectiveTime value="20250411"/>
                                       <component>
                                          <observationMedia ID="MM3">
                                             <text>Figure 2</text>
                                             <value xsi:type="ED" mediaType="image/jpeg">
                                                <reference value="alogliptin-03.jpg"/>
                                             </value>
                                          </observationMedia>
                                       </component>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="dd150950-fc62-4a86-92a1-53dc5154b813"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250411"/>
               <component>
                  <section ID="S13.1">
                     <id root="d928504e-b607-45dd-89b8-e8adbfdd06bb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="Underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Rats were administered oral doses of 75, 400 and 800 mg/kg alogliptin for two years. No drug-related tumors were observed up to 75 mg/kg or approximately 32 times the maximum recommended clinical dose of 25 mg, based on area under the plasma concentration curve (AUC) exposure. At higher doses (approximately 308 times the maximum recommended clinical dose of 25 mg), a combination of thyroid C-cell adenomas and carcinomas increased in male but not female rats. No drug-related tumors were observed in mice after administration of 50, 150 or 300 mg/kg alogliptin for two years, or up to approximately 51 times the maximum recommended clinical dose of 25 mg, based on AUC exposure.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Alogliptin was not mutagenic or clastogenic, with and without metabolic activation, in the Ames test with<content styleCode="italics"> S. typhimurium </content>and<content styleCode="italics"> E. coli </content>or the cytogenetic assay in mouse lymphoma cells. Alogliptin was negative in the<content styleCode="italics"> in vivo </content>mouse micronucleus study.</paragraph>
                        <paragraph>
                           <content styleCode="Underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>In a fertility study in rats, alogliptin had no adverse effects on early embryonic development, mating or fertility at doses up to 500 mg/kg, or approximately 172 times the clinical dose based on plasma drug exposure (AUC).</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="bacb2b6a-aadc-4fdb-81c5-2275c70e29c2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250411"/>
               <component>
                  <section ID="S14.1">
                     <id root="b102af41-aae1-4b37-a9d5-8108ce1c3a09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Overview of Clinical Trials in Adults with Type 2 Diabetes Mellitus</title>
                     <text>
                        <paragraph>Alogliptin tablets have been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione (either alone or in combination with metformin or a sulfonylurea) and insulin (either alone or in combination with metformin).</paragraph>
                        <paragraph>A total of 14,053 patients with type 2 diabetes mellitus were randomized in 11 double-blind, placebo- or active-controlled clinical safety and efficacy trials conducted to evaluate the effects of alogliptin tablets on glycemic control. The racial distribution of patients exposed to trials medication was 70% White, 17% Asian, 6% Black or African American, 2% American Indian or Alaska Native, 0% Native Hawaiian/Other Pacific Islander and 5% Multiracial or other racial groups. The ethnic distribution was 30% Hispanic or Latino. Patients had an overall mean age of 57 years (range 21 to 91 years).</paragraph>
                        <paragraph>In patients with type 2 diabetes mellitus, treatment with alogliptin tablets produced clinically meaningful and statistically significant improvements in hemoglobin A1c (A1C) compared to placebo. As is typical for trials of agents to treat type 2 diabetes mellitus, the mean reduction in A1C with alogliptin tablets appears to be related to the degree of A1C elevation at baseline.</paragraph>
                        <paragraph>Alogliptin tablets had similar changes from baseline in serum lipids compared to placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="d7a5a6af-691b-4f13-a122-cbb84f5542a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Patients with Inadequate Glycemic Control on Diet and Exercise</title>
                     <text>
                        <paragraph>A total of 1,768 patients with type 2 diabetes mellitus participated in three double-blind trials to evaluate the efficacy and safety of alogliptin tablets in patients with inadequate glycemic control on diet and exercise. All three trials had a four week, single-blind, placebo run-in period followed by a 26 week randomized treatment period. Patients who failed to meet prespecified hyperglycemic goals during the 26 week treatment periods received glycemic rescue therapy.</paragraph>
                        <paragraph>In a 26 week, double-blind, placebo-controlled trial, a total of 329 patients (mean baseline A1C = 8%) were randomized to receive alogliptin tablets 12.5 mg, alogliptin tablets 25 mg or placebo once daily. Treatment with alogliptin tablets 25 mg resulted in statistically significant improvements from baseline in A1C and fasting plasma glucose (FPG) compared to placebo at Week 26<content styleCode="italics"> (Table 3)</content>. A total of 8% of patients receiving alogliptin tablets 25 mg and 30% of those receiving placebo required glycemic rescue therapy.</paragraph>
                        <paragraph>Improvements in A1C were not affected by gender, age or baseline body mass index (BMI).</paragraph>
                        <paragraph>The mean change in body weight with alogliptin tablets was similar to placebo.</paragraph>
                        <table ID="table3" width="75%">
                           <caption>Table 3. Glycemic Parameters at Week 26 in a Placebo-Controlled Monotherapy Trial of Alogliptin Tablets<footnote ID="t3f1">Intent-to-treat population using last observation in the trial</footnote>
                           </caption>
                           <col width="33%" align="left" valign="top"/>
                           <col width="34%" align="center" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Alogliptin Tablets<br/>25 mg</th>
                                 <th styleCode="Rrule" valign="bottom">Placebo</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">A1C (%)</content>
                                 </td>
                                 <td styleCode="Rrule">N=128</td>
                                 <td styleCode="Rrule">N=63</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                 <td styleCode="Rrule">7.9</td>
                                 <td styleCode="Rrule">8.0</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnote ID="t3f2">Least squares means adjusted for treatment, baseline value, geographic region and duration of diabetes mellitus</footnote>)</td>
                                 <td styleCode="Rrule">-0.6</td>
                                 <td styleCode="Rrule">0</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t3f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-0.6<footnote ID="t3f3">p&lt;0.01 compared to placebo</footnote> (-0.8, -0.3)</td>
                                 <td styleCode="Rrule">˗</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  % of patients (n/N) achieving A1C ≤7%</td>
                                 <td styleCode="Rrule">44% (58/131)<footnoteRef IDREF="t3f3"/>
                                 </td>
                                 <td styleCode="Rrule">23% (15/64)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">FPG (mg/dL)</content>
                                 </td>
                                 <td styleCode="Rrule">N=129</td>
                                 <td styleCode="Rrule">N=64</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                 <td styleCode="Rrule">172</td>
                                 <td styleCode="Rrule">173</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t3f2"/>)</td>
                                 <td styleCode="Rrule">-16</td>
                                 <td styleCode="Rrule">11</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t3f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-28<footnoteRef IDREF="t3f3"/> (-40, -15)</td>
                                 <td styleCode="Rrule">˗</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a 26 week, double-blind, active-controlled trial, a total of 655 patients (mean baseline A1C = 8.8%) were randomized to receive alogliptin tablets 25 mg alone, pioglitazone 30 mg alone, alogliptin tablets 12.5 mg with pioglitazone 30 mg or alogliptin tablets 25 mg with pioglitazone 30 mg once daily. Coadministration of alogliptin tablets 25 mg with pioglitazone 30 mg resulted in statistically significant improvements from baseline in A1C and FPG compared to alogliptin tablets 25 mg alone and to pioglitazone 30 mg alone<content styleCode="italics"> (Table 4)</content>. A total of 3% of patients receiving alogliptin tablets 25 mg coadministered with pioglitazone 30 mg, 11% of those receiving alogliptin tablets 25 mg alone and 6% of those receiving pioglitazone 30 mg alone required glycemic rescue.</paragraph>
                        <paragraph>Improvements in A1C were not affected by gender, age or baseline BMI.</paragraph>
                        <paragraph>The mean increase in body weight was similar between pioglitazone alone and alogliptin tablets when coadministered with pioglitazone.</paragraph>
                        <table ID="table4" width="75%">
                           <caption>Table 4. Glycemic Parameters at Week 26 in an Active-Controlled Trial of Alogliptin Tablets, Pioglitazone, and Alogliptin Tablets in Combination with Pioglitazone<footnote ID="t4f1">Intent-to-treat population using last observation carried forward</footnote>
                           </caption>
                           <col width="33%" align="left" valign="top"/>
                           <col width="23%" align="center" valign="middle"/>
                           <col width="22%" align="center" valign="middle"/>
                           <col width="22%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" valign="bottom">Alogliptin Tablets<br/>25 mg</th>
                                 <th styleCode="Rrule" valign="bottom">Pioglitazone<br/>30 mg</th>
                                 <th styleCode="Rrule" valign="bottom">Alogliptin Tablets 25 mg<br/>+ Pioglitazone 30 mg</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">A1C (%)</content>
                                 </td>
                                 <td styleCode="Rrule">N=160</td>
                                 <td styleCode="Rrule">N=153</td>
                                 <td styleCode="Rrule">N=158</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                 <td styleCode="Rrule">8.8</td>
                                 <td styleCode="Rrule">8.8</td>
                                 <td styleCode="Rrule">8.8</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnote ID="t4f2">Least squares means adjusted for treatment, geographic region and baseline value</footnote>)</td>
                                 <td styleCode="Rrule">-1.0</td>
                                 <td styleCode="Rrule">-1.2</td>
                                 <td styleCode="Rrule">-1.7</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from alogliptin tablets 25 mg (adjusted mean<footnoteRef IDREF="t4f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">-0.8<footnote ID="t4f3">p&lt;0.01 compared to alogliptin tablets 25 mg or pioglitazone 30 mg</footnote> (-1.0, -0.5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from pioglitazone 30 mg (adjusted mean<footnoteRef IDREF="t4f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">-0.6<footnoteRef IDREF="t4f3"/> (-0.8, -0.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  % of Patients (n/N) achieving A1C ≤7%</td>
                                 <td styleCode="Rrule">24% (40/164)</td>
                                 <td styleCode="Rrule">34% (55/163)</td>
                                 <td styleCode="Rrule">63% (103/164)<footnoteRef IDREF="t4f3"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">FPG (mg/dL)</content>
                                 </td>
                                 <td styleCode="Rrule">N=162</td>
                                 <td styleCode="Rrule">N=157</td>
                                 <td styleCode="Rrule">N=162</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                 <td styleCode="Rrule">189</td>
                                 <td styleCode="Rrule">189</td>
                                 <td styleCode="Rrule">185</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t4f2"/>)</td>
                                 <td styleCode="Rrule">-26</td>
                                 <td styleCode="Rrule">-37</td>
                                 <td styleCode="Rrule">-50</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from alogliptin tablets 25 mg (adjusted mean<footnoteRef IDREF="t4f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">-24<footnoteRef IDREF="t4f3"/> (-34, -15)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Difference from pioglitazone 30 mg (adjusted mean<footnoteRef IDREF="t4f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">˗</td>
                                 <td styleCode="Rrule">-13<footnoteRef IDREF="t4f3"/> (-22, -4)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a 26 week, double-blind, placebo-controlled trial, a total of 784 patients inadequately controlled on diet and exercise alone (mean baseline A1C = 8.4%) were randomized to one of seven treatment groups: placebo; metformin HCl 500 mg or metformin HCl 1000 mg twice daily; alogliptin tablets 12.5 mg twice daily; alogliptin tablets 25 mg daily; or alogliptin tablets 12.5 mg in combination with metformin HCl 500 mg or metformin HCl 1000 mg twice daily. Both coadministration treatment arms (alogliptin tablets 12.5 mg + metformin HCl 500 mg and alogliptin tablets 12.5 mg + metformin HCl 1000 mg) resulted in statistically significant improvements in A1C and FPG when compared with their respective individual alogliptin and metformin component regimens<content styleCode="italics"> (Table 5)</content>. Coadministration treatment arms demonstrated improvements in two hour postprandial glucose (PPG) compared to alogliptin tablets alone or metformin alone<content styleCode="italics"> (Table 5)</content>. A total of 12.3% of patients receiving alogliptin tablets 12.5 mg + metformin HCl 500 mg, 2.6% of patients receiving alogliptin tablets 12.5 mg + metformin HCl 1000 mg, 17.3% of patients receiving alogliptin tablets 12.5 mg, 22.9% of patients receiving metformin HCl 500 mg, 10.8% of patients receiving metformin HCl 1000 mg and 38.7% of patients receiving placebo required glycemic rescue.</paragraph>
                        <paragraph>Improvements in A1C were not affected by gender, age, race or baseline BMI. The mean decrease in body weight was similar between metformin alone and alogliptin tablets when coadministered with metformin.</paragraph>
                        <table ID="table5" width="100%">
                           <caption>Table 5. Glycemic Parameters at Week 26 for Alogliptin Tablets and Metformin Alone and in Combination in Adult Patients with Type 2 Diabetes Mellitus</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="14%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Placebo</th>
                                 <th styleCode="Rrule">Alogliptin Tablets<br/> 12.5 mg<br/>Twice Daily</th>
                                 <th styleCode="Rrule">Metformin HCl<br/>500 mg<br/>Twice Daily</th>
                                 <th styleCode="Rrule">Metformin HCl<br/>1000 mg<br/>Twice Daily</th>
                                 <th styleCode="Rrule">Alogliptin Tablets 12.5 mg + Metformin HCl<br/>500 mg<br/>Twice Daily</th>
                                 <th styleCode="Rrule">Alogliptin Tablets 12.5 mg + Metformin HCl<br/>1000 mg<br/>Twice Daily</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">A1C (%)<footnote ID="t5f1">Intent-to-treat population using last observation on trial prior to discontinuation of double-blind trial medication or sulfonylurea rescue therapy for patients needing rescue</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">N=102</td>
                                 <td styleCode="Rrule">N=104</td>
                                 <td styleCode="Rrule">N=103</td>
                                 <td styleCode="Rrule">N=108</td>
                                 <td styleCode="Rrule">N=102</td>
                                 <td styleCode="Rrule">N=111</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Baseline (mean)</td>
                                 <td styleCode="Rrule">8.5</td>
                                 <td styleCode="Rrule">8.4</td>
                                 <td styleCode="Rrule">8.5</td>
                                 <td styleCode="Rrule">8.4</td>
                                 <td styleCode="Rrule">8.5</td>
                                 <td styleCode="Rrule">8.4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Change from baseline (adjusted mean<footnote ID="t5f2">Least squares means adjusted for treatment, geographic region and baseline value</footnote>)</td>
                                 <td styleCode="Rrule">0.1</td>
                                 <td styleCode="Rrule">-0.6</td>
                                 <td styleCode="Rrule">-0.7</td>
                                 <td styleCode="Rrule">-1.1</td>
                                 <td styleCode="Rrule">-1.2</td>
                                 <td styleCode="Rrule">-1.6</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from metformin (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-0.6<footnote ID="t5f3">p&lt;0.05 when compared to metformin and alogliptin tablets alone</footnote>
                                    <br/>(-0.9, -0.3)</td>
                                 <td styleCode="Rrule">-0.4<footnoteRef IDREF="t5f3"/>
                                    <br/>(-0.7, -0.2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from Alogliptin Tablets (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-0.7<footnoteRef IDREF="t5f3"/>
                                    <br/>(-1.0, -0.4)</td>
                                 <td styleCode="Rrule">-1.0<footnoteRef IDREF="t5f3"/>
                                    <br/>(-1.3, -0.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">% of Patients (n/N) achieving A1C &lt;7%<footnote ID="t5f4">Compared using logistic regression</footnote>
                                 </td>
                                 <td styleCode="Rrule">4%<br/>(4/102)</td>
                                 <td styleCode="Rrule">20%<br/>(21/104)</td>
                                 <td styleCode="Rrule">27%<br/>(28/103)</td>
                                 <td styleCode="Rrule">34%<br/>(37/108)</td>
                                 <td styleCode="Rrule">47%<footnoteRef IDREF="t5f3"/>
                                    <br/>(48/102)</td>
                                 <td styleCode="Rrule">59%<footnoteRef IDREF="t5f3"/>
                                    <br/>(66/111)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">FPG (mg/dL)<footnoteRef IDREF="t5f1"/>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule">N=105</td>
                                 <td styleCode="Rrule">N=106</td>
                                 <td styleCode="Rrule">N=106</td>
                                 <td styleCode="Rrule">N=110</td>
                                 <td styleCode="Rrule">N=106</td>
                                 <td styleCode="Rrule">N=112</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Baseline (mean)</td>
                                 <td styleCode="Rrule">187</td>
                                 <td styleCode="Rrule">177</td>
                                 <td styleCode="Rrule">180</td>
                                 <td styleCode="Rrule">181</td>
                                 <td styleCode="Rrule">176</td>
                                 <td styleCode="Rrule">185</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Change from baseline (adjusted mean<footnoteRef IDREF="t5f2"/>)</td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">-10</td>
                                 <td styleCode="Rrule">-12</td>
                                 <td styleCode="Rrule">-32</td>
                                 <td styleCode="Rrule">-32</td>
                                 <td styleCode="Rrule">-46</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from metformin (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-20<footnoteRef IDREF="t5f3"/>
                                    <br/>(-33, -8)</td>
                                 <td styleCode="Rrule">-14<footnoteRef IDREF="t5f3"/>
                                    <br/>(-26, -2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from Alogliptin Tablets (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-22<footnoteRef IDREF="t5f3"/>
                                    <br/>(-35, -10)</td>
                                 <td styleCode="Rrule">-36<footnoteRef IDREF="t5f3"/>
                                    <br/>(-49, -24)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="Bold">2-Hour PPG (mg/dL)</content>
                                    <footnote ID="t5f5">Intent-to-treat population using data available at Week 26</footnote>
                                 </td>
                                 <td styleCode="Rrule">N=26</td>
                                 <td styleCode="Rrule">N=34</td>
                                 <td styleCode="Rrule">N=28</td>
                                 <td styleCode="Rrule">N=37</td>
                                 <td styleCode="Rrule">N=31</td>
                                 <td styleCode="Rrule">N=37</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Baseline (mean)</td>
                                 <td styleCode="Rrule">263</td>
                                 <td styleCode="Rrule">272</td>
                                 <td styleCode="Rrule">247</td>
                                 <td styleCode="Rrule">266</td>
                                 <td styleCode="Rrule">261</td>
                                 <td styleCode="Rrule">268</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Change from baseline (adjusted mean<footnoteRef IDREF="t5f2"/>)</td>
                                 <td styleCode="Rrule">-21</td>
                                 <td styleCode="Rrule">-43</td>
                                 <td styleCode="Rrule">-49</td>
                                 <td styleCode="Rrule">-54</td>
                                 <td styleCode="Rrule">-68</td>
                                 <td styleCode="Rrule">-86<footnoteRef IDREF="t5f3"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from metformin (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-19<br/>(-49, 11)</td>
                                 <td styleCode="Rrule">-32<footnoteRef IDREF="t5f3"/>
                                    <br/>(-58, -5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Difference from Alogliptin Tablets (adjusted mean<footnoteRef IDREF="t5f2"/> with 95% confidence interval)</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-</td>
                                 <td styleCode="Rrule">-25<br/>(-53, -3)</td>
                                 <td styleCode="Rrule">-43<footnoteRef IDREF="t5f3"/>
                                    <br/>(-70, -16)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="7ce82258-e2f3-45b3-a5d4-e7818a081ef4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3	Combination Therapy</title>
                     <effectiveTime value="20250411"/>
                     <component>
                        <section>
                           <id root="98f828cd-430d-42fc-bc4f-26b8deebdb67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Add-On Therapy to Metformin</content>
                              </paragraph>
                              <paragraph>A total of 2081 patients with type 2 diabetes mellitus participated in two 26 week, double-blind, placebo-controlled trials to evaluate the efficacy and safety of alogliptin tablets as add-on therapy to metformin. In both trials, patients were inadequately controlled on metformin at a dose of at least 1500 mg per day or at the maximum tolerated dose. All patients entered a four week, single-blind placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26 week treatment periods received glycemic rescue therapy.</paragraph>
                              <paragraph>In the first 26 week, placebo-controlled trial, a total of 527 patients already on metformin (mean baseline A1C = 8%) were randomized to receive alogliptin tablets 12.5 mg, alogliptin tablets 25 mg or placebo. Patients were maintained on a stable dose of metformin (median dose = 1700 mg) during the treatment period. Alogliptin tablets 25 mg in combination with metformin resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo<content styleCode="italics"> (Table 6)</content>. A total of 8% of patients receiving alogliptin tablets 25 mg and 24% of patients receiving placebo required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age, baseline BMI or baseline metformin dose.</paragraph>
                              <paragraph>The mean decrease in body weight was similar between alogliptin tablets and placebo when given in combination with metformin.</paragraph>
                              <table ID="table6" width="100%">
                                 <caption>Table 6.  Glycemic Parameters at Week 26 in a Placebo-Controlled Trial of Alogliptin Tablets as Add-On Therapy to Metformin in Adults with Type 2 Diabetes Mellitus<footnote ID="t6f1">Intent-to-treat population using last observation on Trial</footnote>
                                 </caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="middle"/>
                                 <col width="34%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Metformin</th>
                                       <th styleCode="Rrule">Placebo + Metformin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=203</td>
                                       <td styleCode="Rrule">N=103</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">7.9</td>
                                       <td styleCode="Rrule">8.0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnote ID="t6f2">Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose</footnote>)</td>
                                       <td styleCode="Rrule">-0.6</td>
                                       <td styleCode="Rrule">-0.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t6f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-0.5<footnote ID="t6f3">p&lt;0.001 compared to placebo</footnote> (-0.7, -0.3)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % of patients (n/N) achieving A1C ≤7%</td>
                                       <td styleCode="Rrule">44% (92/207)<footnoteRef IDREF="t6f3"/>
                                       </td>
                                       <td styleCode="Rrule">18% (19/104)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">FPG (mg/dL)</content>
                                       </td>
                                       <td styleCode="Rrule">N=204</td>
                                       <td styleCode="Rrule">N=104</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">172</td>
                                       <td styleCode="Rrule">180</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t6f2"/>)</td>
                                       <td styleCode="Rrule">-17</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t6f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-17<footnoteRef IDREF="t6f3"/> (-26, -9)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the second 26 week, double-blind, placebo-controlled Trial, a total of 1,554 patients already on metformin (mean baseline A1C = 8.5%) were randomized to one of 12 double-blind treatment groups: placebo; 12.5 mg or 25 mg of alogliptin tablets alone; 15 mg, 30 mg or 45 mg of pioglitazone alone; or 12.5 mg or 25 mg of alogliptin tablets in combination with 15 mg, 30 mg or 45 mg of pioglitazone. Patients were maintained on a stable dose of metformin (median dose = 1700 mg) during the treatment period. Coadministration of alogliptin tablets and pioglitazone provided statistically significant improvements in A1C and FPG compared to placebo, to alogliptin tablets alone or to pioglitazone alone when added to background metformin therapy<content styleCode="italics"> (Table 7, Figure 3)</content>. In addition, improvements from baseline A1C were comparable between alogliptin tablets alone and pioglitazone alone (15 mg, 30 mg and 45 mg) at Week 26. A total of 4%, 5% or 2% of patients receiving alogliptin tablets 25 mg with 15 mg, 30 mg or 45 mg pioglitazone, 33% of patients receiving placebo, 13% of patients receiving alogliptin tablets 25 mg and 10%, 15% or 9% of patients receiving pioglitazone 15 mg, 30 mg or 45 mg alone required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age or baseline BMI.</paragraph>
                              <paragraph>The mean increase in body weight was similar between pioglitazone alone and alogliptin tablets when coadministered with pioglitazone.</paragraph>
                              <table ID="table7" width="100%">
                                 <caption>Table 7. Glycemic Parameters in a 26 Week Trial of Alogliptin Tablets, Pioglitazone and Alogliptin Tablets in Combination with Pioglitazone when Added to Metformin in Adults with Type 2 Diabetes Mellitus<footnote ID="t7f1">Intent-to-treat population using last observation in the trial</footnote>
                                 </caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Placebo</th>
                                       <th styleCode="Rrule">Alogliptin Tablets<br/>25 mg</th>
                                       <th styleCode="Rrule">Pioglitazone 15 mg</th>
                                       <th styleCode="Rrule">Pioglitazone 30 mg</th>
                                       <th styleCode="Rrule">Pioglitazone 45 mg</th>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Pioglitazone 15 mg</th>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Pioglitazone 30 mg</th>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Pioglitazone 45 mg</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=126</td>
                                       <td styleCode="Rrule">N=123</td>
                                       <td styleCode="Rrule">N=127</td>
                                       <td styleCode="Rrule">N=123</td>
                                       <td styleCode="Rrule">N=126</td>
                                       <td styleCode="Rrule">N=127</td>
                                       <td styleCode="Rrule">N=124</td>
                                       <td styleCode="Rrule">N=126</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Baseline<br/>(mean)</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.6</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.5</td>
                                       <td styleCode="Rrule">8.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Change from baseline (adjusted mean<footnote ID="t7f2">Least squares means adjusted for treatment, geographic region, metformin dose and baseline value</footnote>)</td>
                                       <td styleCode="Rrule">-0.1</td>
                                       <td styleCode="Rrule">-0.9</td>
                                       <td styleCode="Rrule">-0.8</td>
                                       <td styleCode="Rrule">-0.9</td>
                                       <td styleCode="Rrule">-1.0</td>
                                       <td styleCode="Rrule">-1.3<footnote ID="t7f3">p≤0.01 when compared to corresponding doses of pioglitazone and alogliptin tablets alone</footnote>
                                       </td>
                                       <td styleCode="Rrule">-1.4<footnoteRef IDREF="t7f3"/>
                                       </td>
                                       <td styleCode="Rrule">-1.6<footnoteRef IDREF="t7f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from pioglitazone (adjusted mean<footnoteRef IDREF="t7f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule">-0.5<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.7, -0.3)</td>
                                       <td styleCode="Rrule">-0.5<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.7, -0.3)</td>
                                       <td styleCode="Rrule">-0.6<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.8,  -0.4)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from Alogliptin Tablets (adjusted mean<footnoteRef IDREF="t7f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-0.4<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.6, -0.1)</td>
                                       <td styleCode="Rrule">-0.5<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.7, -0.3)</td>
                                       <td styleCode="Rrule">-0.7<footnoteRef IDREF="t7f3"/>
                                          <br/>(-0.9, -0.5)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" valign="middle">Patients (%) achieving A1C ≤7%</td>
                                       <td styleCode="Rrule">6%<br/>(8/129)</td>
                                       <td styleCode="Rrule">27%<br/>(35/129)</td>
                                       <td styleCode="Rrule">26%<br/>(33/129)</td>
                                       <td styleCode="Rrule">30%<br/>(38/129)</td>
                                       <td styleCode="Rrule">36%<br/>(47/129)</td>
                                       <td styleCode="Rrule">55%<br/>(71/130)<footnoteRef IDREF="t7f3"/>
                                       </td>
                                       <td styleCode="Rrule">53%<br/>(69/130)<footnoteRef IDREF="t7f3"/>
                                       </td>
                                       <td styleCode="Rrule">60%<br/>(78/130)<footnoteRef IDREF="t7f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">FPG (mg/dL)</content>
                                       </td>
                                       <td styleCode="Rrule">N=129</td>
                                       <td styleCode="Rrule">N=126</td>
                                       <td styleCode="Rrule">N=127</td>
                                       <td styleCode="Rrule">N=125</td>
                                       <td styleCode="Rrule">N=129</td>
                                       <td styleCode="Rrule">N=130</td>
                                       <td styleCode="Rrule">N=126</td>
                                       <td styleCode="Rrule">N=127</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Baseline<br/>(mean)</td>
                                       <td styleCode="Rrule">177</td>
                                       <td styleCode="Rrule">184</td>
                                       <td styleCode="Rrule">177</td>
                                       <td styleCode="Rrule">175</td>
                                       <td styleCode="Rrule">181</td>
                                       <td styleCode="Rrule">179</td>
                                       <td styleCode="Rrule">179</td>
                                       <td styleCode="Rrule">178</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Change from baseline  (adjusted mean<footnoteRef IDREF="t7f2"/>)</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">-19</td>
                                       <td styleCode="Rrule">-24</td>
                                       <td styleCode="Rrule">-29</td>
                                       <td styleCode="Rrule">-32</td>
                                       <td styleCode="Rrule">-38<footnoteRef IDREF="t7f3"/>
                                       </td>
                                       <td styleCode="Rrule">-42<footnoteRef IDREF="t7f3"/>
                                       </td>
                                       <td styleCode="Rrule">-53<footnoteRef IDREF="t7f3"/>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from pioglitazone (adjusted mean<footnoteRef IDREF="t7f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-14<footnoteRef IDREF="t7f3"/> (-24, -5)</td>
                                       <td styleCode="Rrule">-13<footnoteRef IDREF="t7f3"/> (-23, -3)</td>
                                       <td styleCode="Rrule">-20<footnoteRef IDREF="t7f3"/> (-30, -11)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Difference from Alogliptin Tablets (adjusted mean<footnoteRef IDREF="t7f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-</td>
                                       <td styleCode="Rrule">-19<footnoteRef IDREF="t7f3"/> (-29, -10)</td>
                                       <td styleCode="Rrule">-23<footnoteRef IDREF="t7f3"/> (-33, -13)</td>
                                       <td styleCode="Rrule">-34<footnoteRef IDREF="t7f3"/> (-44, -24)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="Bold">Figure 3.  Change from Baseline in A1C at Week 26 with Alogliptin Tablets and Pioglitazone Alone and Alogliptin Tablets in Combination with Pioglitazone When Added to Metformin in Adults with Type 2 Diabetes Mellitus</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM4"/>
                           </text>
                           <effectiveTime value="20250411"/>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 3</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="alogliptin-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cff6f018-f2ae-4532-b518-bf835445d333"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Add-On Therapy to a Thiazolidinedione</content>
                              </paragraph>
                              <paragraph>In a 26 week, placebo-controlled trial, a total of 493 patients inadequately controlled on a thiazolidinedione alone or in combination with metformin or a sulfonylurea (10 mg) (mean baseline A1C = 8%) were randomized to receive alogliptin tablets 12.5 mg, alogliptin tablets 25 mg or placebo. Patients were maintained on a stable dose of pioglitazone (median dose = 30 mg) during the treatment period; those who were also previously treated on metformin (median dose = 2000 mg) or sulfonylurea (median dose = 10 mg) prior to randomization were maintained on the combination therapy during the treatment period. All patients entered into a four week, single-blind placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26 week treatment period received glycemic rescue therapy.</paragraph>
                              <paragraph>The addition of alogliptin tablets 25 mg once daily to pioglitazone therapy resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, compared to placebo<content styleCode="italics"> (Table 8)</content>. A total of 9% of patients who were receiving alogliptin tablets 25 mg and 12% of patients receiving placebo required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age, baseline BMI or baseline pioglitazone dose.</paragraph>
                              <paragraph>Clinically meaningful reductions in A1C were observed with alogliptin tablets compared to placebo regardless of whether subjects were receiving concomitant metformin or sulfonylurea (-0.2% placebo versus -0.9% alogliptin tablets) therapy or pioglitazone alone (0% placebo versus -0.52% alogliptin tablets).</paragraph>
                              <paragraph>The mean increase in body weight was similar between alogliptin tablets and placebo when given in combination with pioglitazone.</paragraph>
                              <table ID="table8" width="100%">
                                 <caption>Table 8.  Glycemic Parameters in a 26 Week, Placebo-Controlled Trial of Alogliptin Tablets as Add-On Therapy to Pioglitazone in Adult with Type 2 Diabetes Mellitus<footnote ID="t8f1">Intent-to-treat population using last observation on trial</footnote>
                                 </caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="middle"/>
                                 <col width="33%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Pioglitazone ± Metformin ± Sulfonylurea</th>
                                       <th styleCode="Rrule">Placebo + Pioglitazone ± Metformin ± Sulfonylurea</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=195</td>
                                       <td styleCode="Rrule">N=95</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnote ID="t8f2">Least squares means adjusted for treatment, baseline value, geographic region, baseline treatment regimen (pioglitazone, pioglitazone + metformin or pioglitazone + sulfonylurea) and baseline pioglitazone dose</footnote>)</td>
                                       <td styleCode="Rrule">-0.8</td>
                                       <td styleCode="Rrule">-0.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t8f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-0.6<footnote ID="t8f3">p&lt;0.01 compared to placebo</footnote> (-0.8, -0.4)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % of patients (n/N) achieving A1C ≤7%</td>
                                       <td styleCode="Rrule">49% (98/199)<footnoteRef IDREF="t8f3"/>
                                       </td>
                                       <td styleCode="Rrule">34% (33/97)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">FPG (mg/dL)</content>
                                       </td>
                                       <td styleCode="Rrule">N=197</td>
                                       <td styleCode="Rrule">N=97</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">170</td>
                                       <td styleCode="Rrule">172</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t8f2"/>)</td>
                                       <td styleCode="Rrule">-20</td>
                                       <td styleCode="Rrule">-6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t8f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-14<footnoteRef IDREF="t8f3"/> (-23, -5)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="40f48efe-1cb5-4629-9c05-dbfd0c14e7af"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Add-on Combination Therapy with Pioglitazone and Metformin</content>
                              </paragraph>
                              <paragraph>In a 52 week, active-comparator trial, a total of 803 patients inadequately controlled (mean baseline A1C = 8.2%) on a current regimen of pioglitazone 30 mg and metformin at least 1500 mg per day or at the maximum tolerated dose were randomized to either receive the addition of alogliptin tablets 25 mg or the titration of pioglitazone 30 mg to 45 mg following a four week, single-blind placebo run-in period. Patients were maintained on a stable dose of metformin (median dose = 1700 mg). Patients who failed to meet prespecified hyperglycemic goals during the 52 week treatment period received glycemic rescue therapy.</paragraph>
                              <paragraph>In combination with pioglitazone and metformin, alogliptin tablets 25 mg were shown to be statistically superior in lowering A1C and FPG compared with the titration of pioglitazone from 30 mg to 45 mg at Week 26 and at Week 52<content styleCode="italics"> (Table 9; results shown only for Week 52)</content>. A total of 11% of patients in the alogliptin tablets 25 mg treatment group and 22% of patients in the pioglitazone up-titration group required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age, race or baseline BMI.</paragraph>
                              <paragraph>The mean increase in body weight was similar in both treatment arms.</paragraph>
                              <table ID="table9" width="75%">
                                 <caption>Table 9. Glycemic Parameters in a 52 Week, Active-Controlled Trial of Alogliptin Tablets as Add-On Combination Therapy to Metformin and Pioglitazone in Adults with Type 2 Diabetes Mellitus<footnote ID="t9f1">Intent-to-treat population using last observation in the trial</footnote>
                                 </caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="bottom"/>
                                 <col width="30%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Pioglitazone 30 mg + Metformin</th>
                                       <th styleCode="Rrule">Pioglitazone 45 mg + Metformin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=397</td>
                                       <td styleCode="Rrule">N=394</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">8.2</td>
                                       <td styleCode="Rrule">8.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline<br/>(adjusted mean<footnote ID="t9f2">Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose</footnote>)</td>
                                       <td styleCode="Rrule">-0.7</td>
                                       <td styleCode="Rrule">-0.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from pioglitazone 45 mg + metformin<br/>(adjusted mean<footnoteRef IDREF="t9f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-0.4<footnote ID="t9f3">Noninferior and statistically superior to metformin + pioglitazone at the 0.025 one-sided significance level</footnote> (-0.5, -0.3)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % of Patients (n/N) achieving A1C≤7%</td>
                                       <td styleCode="Rrule">33% (134/404)<footnote ID="t9f4">p&lt;0.001 compared to pioglitazone 45 mg + metformin</footnote>
                                       </td>
                                       <td styleCode="Rrule">21% (85/399)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">Fasting Plasma Glucose (mg/dL)<footnoteRef IDREF="t9f3"/>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule">N=399</td>
                                       <td styleCode="Rrule">N=396</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">162</td>
                                       <td styleCode="Rrule">162</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t9f2"/>)</td>
                                       <td styleCode="Rrule">-15</td>
                                       <td styleCode="Rrule">-4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from pioglitazone 45 mg + metformin<br/>(adjusted mean<footnoteRef IDREF="t9f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-11<footnoteRef IDREF="t9f4"/> (-16, -6)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b7379ac6-8043-4c0d-ab16-b438fd2acb3d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Add-On Therapy to a Sulfonylurea</content>
                              </paragraph>
                              <paragraph>In a 26 week, placebo-controlled trial, a total of 500 patients inadequately controlled on a sulfonylurea (mean baseline A1C = 8.1%) were randomized to receive alogliptin tablets 12.5 mg, alogliptin tablets 25 mg or placebo. Patients were maintained on a stable dose of glyburide (median dose = 10 mg) during the treatment period. All patients entered into a four week, single-blind, placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26 week treatment period received glycemic rescue therapy.</paragraph>
                              <paragraph>The addition of alogliptin tablets 25 mg to glyburide therapy resulted in statistically significant improvements from baseline in A1C at Week 26 when compared to placebo<content styleCode="italics"> (Table 10)</content>. Improvements in FPG observed with alogliptin tablets 25 mg were not statistically significant compared with placebo. A total of 16% of patients receiving alogliptin tablets 25 mg and 28% of those receiving placebo required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age, baseline BMI or baseline glyburide dose.</paragraph>
                              <paragraph>The mean change in body weight was similar between alogliptin tablets and placebo when given in combination with glyburide.</paragraph>
                              <table ID="table10" width="100%">
                                 <caption>Table 10. Glycemic Parameters in a 26 Week, Placebo-Controlled Trial of Alogliptin Tablets as Add-On Therapy to Glyburide in Adults with Type 2 Diabetes Mellitus<footnote ID="t10f1">Intent-to-treat population using last observation on trial</footnote>
                                 </caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Glyburide</th>
                                       <th styleCode="Rrule">Placebo + Glyburide</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=197</td>
                                       <td styleCode="Rrule">N=97</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">8.1</td>
                                       <td styleCode="Rrule">8.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline<br/>(adjusted mean<footnote ID="t10f2">Least squares means adjusted for treatment, baseline value, geographic region and baseline glyburide dose</footnote>)</td>
                                       <td styleCode="Rrule">-0.5</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo<br/>(adjusted mean<footnoteRef IDREF="t10f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-0.5<footnote ID="t10f3">p&lt;0.01 compared to placebo</footnote> (-0.7, -0.3)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % of Patients (n/N) achieving A1C ≤7%</td>
                                       <td styleCode="Rrule">35% (69/198)<footnoteRef IDREF="t10f3"/>
                                       </td>
                                       <td styleCode="Rrule">18% (18/99)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">FPG (mg/dL)</content>
                                       </td>
                                       <td styleCode="Rrule">N=198</td>
                                       <td styleCode="Rrule">N=99</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">174</td>
                                       <td styleCode="Rrule">177</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline<br/>(adjusted mean<footnoteRef IDREF="t10f2"/>)</td>
                                       <td styleCode="Rrule">-8</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo<br/>(adjusted mean<footnoteRef IDREF="t10f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-11 (-22, 1)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="571ef166-64ea-4fe3-bd98-5b6bc8e25962"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="Bold italics">Add-On Therapy to Insulin</content>
                              </paragraph>
                              <paragraph>In a 26 week, placebo-controlled trial, a total of 390 patients inadequately controlled on insulin alone (42%) or in combination with metformin (58%) (mean baseline A1C = 9.3%) were randomized to receive alogliptin tablets 12.5 mg, alogliptin tablets 25 mg or placebo. Patients were maintained on their insulin regimen (median dose = 55 IU) upon randomization and those previously treated with insulin in combination with metformin (median dose = 1700 mg) prior to randomization continued on the combination regimen during the treatment period. Patients entered the trial on short-, intermediate- or long-acting (basal) insulin or premixed insulin. Patients who failed to meet prespecified hyperglycemic goals during the 26 week treatment period received glycemic rescue therapy.</paragraph>
                              <paragraph>The addition of alogliptin tablets 25 mg once daily to insulin therapy resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo<content styleCode="italics"> (Table 11)</content>. A total of 20% of patients receiving alogliptin tablets 25 mg and 40% of those receiving placebo required glycemic rescue.</paragraph>
                              <paragraph>Improvements in A1C were not affected by gender, age, baseline BMI or baseline insulin dose. Clinically meaningful reductions in A1C were observed with alogliptin tablets compared to placebo regardless of whether subjects were receiving concomitant metformin and insulin (-0.2% placebo versus -0.8% alogliptin tablets) therapy or insulin alone (0.1% placebo versus -0.7% alogliptin tablets).</paragraph>
                              <paragraph>The mean increase in body weight was similar between alogliptin tablets and placebo when given in combination with insulin.</paragraph>
                              <table ID="table11" width="100%">
                                 <caption>Table 11. Glycemic Parameters in a 26 Week, Placebo-Controlled Trial of Alogliptin Tablets as Add-On Therapy to Insulin in Adults with Type 2 Diabetes Mellitus<footnote ID="t11f1">Intent-to-treat population using last observation in the trial</footnote>
                                 </caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="middle"/>
                                 <col width="33%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alogliptin Tablets 25 mg + Insulin ± Metformin</th>
                                       <th styleCode="Rrule">Placebo + Insulin ± Metformin</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">A1C (%)</content>
                                       </td>
                                       <td styleCode="Rrule">N=126</td>
                                       <td styleCode="Rrule">N=126</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">9.3</td>
                                       <td styleCode="Rrule">9.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnote ID="t11f2">Least squares means adjusted for treatment, baseline value, geographic region, baseline treatment regimen (insulin or insulin + metformin) and baseline daily insulin dose</footnote>)</td>
                                       <td styleCode="Rrule">-0.7</td>
                                       <td styleCode="Rrule">-0.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t11f2"/> with 95% confidence interval) </td>
                                       <td styleCode="Rrule">-0.6<footnote ID="t11f3">p&lt;0.05 compared to placebo</footnote> (-0.8, -0.4)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  % of patients (n/N) achieving A1C ≤7%</td>
                                       <td styleCode="Rrule">8% (10/129)</td>
                                       <td styleCode="Rrule">1% (1/129)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="Bold">FPG (mg/dL)</content>
                                       </td>
                                       <td styleCode="Rrule">N=128</td>
                                       <td styleCode="Rrule">N=127</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Baseline (mean)</td>
                                       <td styleCode="Rrule">186</td>
                                       <td styleCode="Rrule">196</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Change from baseline (adjusted mean<footnoteRef IDREF="t11f2"/>)</td>
                                       <td styleCode="Rrule">-12</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Difference from placebo (adjusted mean<footnoteRef IDREF="t11f2"/> with 95% confidence interval)</td>
                                       <td styleCode="Rrule">-18<footnoteRef IDREF="t11f3"/> (-33, -2)</td>
                                       <td styleCode="Rrule">˗</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250411"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="7244dc0e-35bd-4b88-87fd-72e1046613db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4	Cardiovascular Safety Trial</title>
                     <text>
                        <paragraph>A randomized, double-blind, placebo-controlled cardiovascular outcomes trial (EXAMINE) was conducted to evaluate the cardiovascular risk of alogliptin tablets. The trial compared the risk of major adverse cardiovascular events (MACE) between alogliptin tablets (N=2701) and placebo (N=2679) when added to standard of care therapies for diabetes mellitus and atherosclerotic vascular disease (ASCVD). The trial was event driven and patients were followed until a sufficient number of primary outcome events accrued.</paragraph>
                        <paragraph>Eligible patients were adults with type 2 diabetes mellitus who had inadequate glycemic control at baseline (e.g., HbA1c &gt;6.5%) and had been hospitalized for an acute coronary syndrome event (e.g., acute myocardial infarction or unstable angina requiring hospitalization) 15 to 90 days prior to randomization. The dose of alogliptin tablets was based on estimated renal function at baseline per dosage and administration recommendations<content styleCode="italics"> [see<linkHtml href="#S2.2"> Dosage and Administration (2.2)</linkHtml>]</content>. The average time between an acute coronary syndrome event and randomization was approximately 48 days.</paragraph>
                        <paragraph>The mean age of the population was 61 years. Most patients were male (68%), White (73%), and were recruited from outside of the United States (86%). Asian and Black or African American patients contributed 20% and 4% of the total population, respectively. At the time of randomization patients had a diagnosis of type 2 diabetes mellitus for approximately 9 years, 87% had a prior myocardial infarction and 14% were current smokers. Hypertension (83%) and renal impairment (27% with an eGFR ≤60 mL/min/1.73 m<sup>2</sup>) were prevalent co-morbid conditions. Use of medications to treat diabetes mellitus (e.g., metformin 73%, sulfonylurea 54%, insulin 41%), and ASCVD (e.g., statin 94%, aspirin 93%, renin-angiotensin system blocker 88%, beta-blocker 87%) was similar between patients randomized to alogliptin tablets and placebo at baseline. During the trial, medications to treat diabetes mellitus and ASCVD could be adjusted to ensure care for these conditions adhered to standard of care recommendations set by local practice guidelines.</paragraph>
                        <paragraph>The primary endpoint in EXAMINE was the time to first occurrence of a MACE defined as the composite of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke. The trial was designed to exclude a pre-specified risk margin of 1.3 for the hazard ratio of MACE. The median exposure to trial drug was 526 days and 95% of the patients were followed to trial completion or death.</paragraph>
                        <paragraph>Table 12 shows the trial results for the primary MACE composite endpoint and the contribution of each component to the primary MACE endpoint. The upper bound of the confidence interval was 1.16 and excluded a risk margin larger than 1.3.</paragraph>
                        <table ID="table12" width="75%">
                           <caption>Table 12. Patients with MACE and Type 2 Diabetes Mellitus in EXAMINE </caption>
                           <col width="16%" align="left" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="16%" align="center" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <col width="17%" align="center" valign="bottom"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="4">
                                    <content styleCode="bold">Composite of first event of CV death, nonfatal MI or nonfatal stroke  (MACE)</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">
                                    <content styleCode="bold">Alogliptin</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <content styleCode="bold">Hazard Ratio</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center" valign="middle">
                                    <content styleCode="bold">Number of Patients (%)</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Rate per 100 PY</content>
                                    <footnote ID="t12f1">Patient Years (PY)</footnote>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Number of Patients (%)</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Rate per 100 PY</content>
                                    <footnoteRef IDREF="t12f1"/>
                                 </td>
                                 <td styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">(98% CI)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">N=2701</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">N=2679</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">305 (11.3)</td>
                                 <td styleCode="Rrule">7.6</td>
                                 <td styleCode="Rrule">316 (11.8)</td>
                                 <td styleCode="Rrule">7.9</td>
                                 <td styleCode="Rrule">0.96 (0.80, 1.16)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  CV Death</td>
                                 <td styleCode="Rrule">89 (3.3)</td>
                                 <td styleCode="Rrule">2.2</td>
                                 <td styleCode="Rrule">111 (4.1)</td>
                                 <td styleCode="Rrule">2.8</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Non-fatal MI</td>
                                 <td styleCode="Rrule">187 (6.9)</td>
                                 <td styleCode="Rrule">4.6</td>
                                 <td styleCode="Rrule">173 (6.5)</td>
                                 <td styleCode="Rrule">4.3</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Non-fatal stroke</td>
                                 <td styleCode="Rrule" valign="bottom">29 (1.1)</td>
                                 <td styleCode="Rrule" valign="bottom">0.7</td>
                                 <td styleCode="Rrule" valign="bottom">32 (1.2)</td>
                                 <td styleCode="Rrule" valign="bottom">0.8</td>
                                 <td styleCode="Rrule" valign="bottom"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The Kaplan-Meier based cumulative event probability is presented in Figure 4 for the time to first occurrence of the primary MACE composite endpoint by treatment arm. The curves for placebo and alogliptin tablets overlap throughout the duration of the trial. The observed incidence of MACE was highest within the first 60 days after randomization in both treatment arms (14.8 MACE per 100 PY), decreased from day 60 to the end of the first year (8.4 per 100 PY) and was lowest after one year of follow-up (5.2 per 100 PY).</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="Bold">Figure 4. Observed Cumulative Rate of MACE in EXAMINE</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM5"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The rate of all cause death was similar between treatment arms with 153 (3.6 per 100 PY) recorded among patients randomized to alogliptin tablets and 173 (4.1 per 100 PY) among patients randomized to placebo. A total of 112 deaths (2.9 per 100 PY) among patients on alogliptin tablets and 130 among patients on placebo (3.5 per 100 PY) were adjudicated as cardiovascular deaths.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="alogliptin-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="ef5d258f-5950-4b3b-9da2-ccdc0e2a8235"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Alogliptin tablets are available as film-coated tablets containing 25 mg, 12.5 mg or 6.25 mg of alogliptin as follows:</paragraph>
                  <paragraph>25 mg tablet: light red, oval, biconvex, film-coated, with "TAK ALG-25" printed on one side, available in:</paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>  NDC 45802-150-65</td>
                           <td>Bottles of 30 tablets</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>12.5 mg tablet: yellow, oval, biconvex, film-coated, with "TAK ALG-12.5" printed on one side, available in:</paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>  NDC 45802-103-65</td>
                           <td>Bottles of 30 tablets</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>6.25 mg tablet: light pink, oval, biconvex, film-coated, with "TAK ALG-6.25" printed on one side, available in:</paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>  NDC 45802-087-65</td>
                           <td>Bottles of 30 tablets</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <section>
                     <id root="444d640c-c0b1-44b2-ad2b-285378f26f4d"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="efff69b8-533d-4a83-b7e5-2c0316deaad2"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <section>
                     <id root="c6b443f2-dada-4a2a-8dd0-8a66f6f412e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pancreatitis </content>
                        </paragraph>
                        <paragraph>Inform patients that acute pancreatitis has been reported during use of alogliptin tablets. Educate patients that persistent, severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Instruct patients to promptly discontinue alogliptin tablets and contact their physician if persistent severe abdominal pain occurs <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="30f4d71b-8b33-48f6-9793-e33d1a33c2cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Heart Failure</content>
                        </paragraph>
                        <paragraph>Inform patients of the signs and symptoms of heart failure. Before initiating alogliptin tablets, patients should be asked about a history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their healthcare providers as soon as possible if they experience symptoms of heart failure, including increasing shortness of breath, rapid increase in weight, or swelling of the feet <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2ce04e3e-b712-4550-b36e-bf9eb68d8cec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that allergic reactions have been reported during use of alogliptin tablets. Instruct patients if symptoms of allergic reactions (including skin rash, hives and swelling of the face, lips, tongue and throat that may cause difficulty in breathing or swallowing) occur, patients should discontinue alogliptin tablets and seek medical advice promptly <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c8b0938c-9e56-42ea-b3ae-b11147b4bc41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hepatic Effects</content>
                        </paragraph>
                        <paragraph>Inform patients that postmarketing reports of liver injury, sometimes fatal, have been reported during use of alogliptin tablets. Instruct patients if signs or symptoms of liver injury occur, patients should discontinue alogliptin tablets and seek medical advice promptly <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="807402a5-744d-4ecd-b31b-470add2aa7e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues</content>
                        </paragraph>
                        <paragraph>Inform patients that hypoglycemia can occur, particularly when an insulin secretagogue or insulin is used in combination with alogliptin tablets. Educate patients about the risks, symptoms and appropriate management of hypoglycemia <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e8a7110e-691a-4cb1-895f-68f9d8cadf51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Severe and Disabling Arthralgia</content>
                        </paragraph>
                        <paragraph>Inform patients that severe and disabling joint pain may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe joint pain occurs <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6631884d-b358-41e6-b18a-1609563e2ce5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Bullous Pemphigoid</content>
                        </paragraph>
                        <paragraph>Inform patients that bullous pemphigoid may occur with this class of drugs. Instruct patients to seek medical advice if blisters or erosions occur<content styleCode="italics"> [see<linkHtml href="#S5.7"> Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f3302005-20e5-45e8-b01e-19311c1a8396"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Dosage</content>
                        </paragraph>
                        <paragraph>Instruct patients to take alogliptin tablets only as prescribed. Instruct patients if a dose is missed, not to double their next dose.</paragraph>
                     </text>
                     <effectiveTime value="20250411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="12003969-d6f5-4237-b83d-21f80bc62258"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>ALO332 R9</paragraph>
                  <paragraph>0Q900 RC PH7</paragraph>
                  <paragraph>Rev 4-25</paragraph>
               </text>
               <effectiveTime value="20250411"/>
            </section>
         </component>
         <component>
            <section>
               <id root="4646b602-bf23-446a-bde8-9769056e287a"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="4%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <col width="22%" align="left" valign="top"/>
                     <col width="18%" align="left" valign="top"/>
                     <col width="18%" align="left" valign="top"/>
                     <col width="18%" align="left" valign="top"/>
                     <tfoot>
                        <tr>
                           <td colspan="4" align="left">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="center">ALO332 R9</td>
                           <td align="right">April 2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6" align="center">
                              <content styleCode="bold">MEDICATION GUIDE<br/>Alogliptin Tablets</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Read this Medication Guide carefully before you start taking alogliptin tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about alogliptin tablets, ask your doctor or pharmacist.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold" ID="whatis">What is the most important information I should know about alogliptin tablets?<br/>Serious side effects can happen to people taking alogliptin tablets, including:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list>
                                 <item>
                                    <caption>1.</caption>
                                    <content styleCode="bold">Inflammation of the pancreas (pancreatitis):</content> Alogliptin tablets may cause pancreatitis which may be severe. <br/>Certain medical conditions make you more likely to get pancreatitis.<br/>
                                    <content styleCode="bold">Before you start taking alogliptin tablets:</content>
                                    <br/>Tell your doctor if you have ever had: 											</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>pancreatitis</item>
                                 <item>high blood triglyceride levels</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>kidney problems</item>
                                 <item>stones in your gallbladder (gall stones)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>liver problems</item>
                                 <item>a history of alcoholism</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="5">Stop taking alogliptin tablets and call your doctor right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list>
                                 <item>
                                    <caption>2.</caption>
                                    <content styleCode="bold">Heart failure:</content> Heart failure means your heart does not pump blood well enough.<br/>
                                    <content styleCode="bold">Before you start taking alogliptin tablets:</content>
                                    <br/>Tell your doctor if you have ever had heart failure or have problems with your kidneys.<br/> Contact your doctor right away if you have any of the following symptoms: 											</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>increasing shortness of breath or trouble breathing especially when lying down</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>an unusually fast increase in weight</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>swelling of feet, ankles, or legs</item>
                                 <item>unusual tiredness</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="5">These may be symptoms of heart failure.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What are alogliptin tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list styleCode="disc" listType="unordered">
                                 <item>Alogliptin tablets are a prescription medicine used along with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes mellitus.</item>
                                 <item>Alogliptin tablets are not for people with type 1 diabetes mellitus.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">It is not known if alogliptin tablets are safe and effective in children under the age of 18.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Who should not take alogliptin tablets?<br/>Do not take alogliptin tablets if you:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>Are allergic to any ingredients in alogliptin tablets or have had a serious allergic (hypersensitivity) reaction to alogliptin tablets. See the end of this Medication Guide for a complete list of the ingredients in alogliptin tablets.<br/>Symptoms of a serious allergic reaction to alogliptin tablets may include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>swelling of your face, lips, throat and other areas on your skin</item>
                                 <item>raised, red areas on your skin (hives)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>difficulty with swallowing or breathing</item>
                                 <item>skin rash, itching, flaking or peeling</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="5">If you have any of these symptoms, stop taking alogliptin tablets and contact your doctor or go to the nearest hospital emergency room right away.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">What should I tell my doctor before and during treatment with alogliptin tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Before you take alogliptin tablets, tell your doctor if you:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="Disc">
                                 <item>have heart failure</item>
                                 <item>have or have had inflammation of your pancreas (pancreatitis)</item>
                                 <item>have kidney or liver problems</item>
                                 <item>have other medical conditions</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if alogliptin tablets can harm your unborn baby. Talk with your doctor about the best way to control your blood sugar while you are pregnant or if you plan to become pregnant</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if alogliptin tablets passes into your breast milk. Talk with your doctor about the best way to feed your baby if you are taking alogliptin tablets</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">Tell your doctor about all the medicines you take, </content>including prescription and over-the-counter medicines, vitamins and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist before you start any new medicine.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Alogliptin tablets may affect the way other medicines work, and other medicines may affect how alogliptin tablets works. Contact your doctor before you start or stop other types of medicines.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">How should I take alogliptin tablets?</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>Take alogliptin tablets exactly as your doctor tells you to take it.</item>
                                 <item>Take alogliptin tablets 1 time each day with or without food.</item>
                                 <item>Do not split tablets.</item>
                                 <item>If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose, and take the next dose at your regular time.<content styleCode="Bold"> Do not </content>take 2 doses of alogliptin tablets at the same time.</item>
                                 <item>If you take too many alogliptin tablets, call your doctor or your Poison Help Line right away at 1-800-222-1222.</item>
                                 <item>If your body is under stress, such as from fever, infection, accident or surgery, the dose of your diabetes mellitus medicines may need to be changed. Call your doctor right away.</item>
                                 <item>Stay on your diet and exercise programs and check your blood sugar as your doctor tells you to.</item>
                                 <item>Your doctor may do certain blood tests before you start alogliptin tablets and during treatment as needed. Your doctor may change your dose of alogliptin tablets based on the results of your blood tests due to how well your kidneys are working.</item>
                                 <item>Your doctor will check your diabetes mellitus with regular blood tests, including your blood sugar levels and your hemoglobin A1C.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What are the possible side effects of alogliptin tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Alogliptin tablets can cause serious side effects, including:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">See "<content styleCode="Bold">
                                 <linkHtml href="#whatis">What is the most important information I should know about alogliptin tablets?</linkHtml>
                              </content>"</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Serious allergic (hypersensitivity) reactions</content> such as:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>swelling of your face, lips, throat and other areas on your skin</item>
                                 <item>raised, red areas on your skin (hives)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>difficulty swallowing or breathing</item>
                                 <item>skin rash, itching, flaking or peeling</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">If you have these symptoms, stop taking alogliptin tablets and contact your doctor right away or go the nearest hospital emergency room.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="Bold">Liver problems.</content> Call your doctor right away or go to the nearest hospital emergency room if you have unexplained symptoms, such as:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>nausea or vomiting</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>stomach pain</item>
                                 <item>dark urine</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>unusual or unexplained tiredness</item>
                                 <item>yellowing of your skin or the whites of your eyes</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="Bold">Low blood sugar (hypoglycemia). </content>If you take alogliptin tablets with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take alogliptin tablets. If you have symptoms of low blood sugar, you should check your blood sugar and treat if low, then call your doctor. Signs and symptoms of low blood sugar include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>shaking or feeling jittery</item>
                                 <item>fast heartbeat</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>sweating</item>
                                 <item>change in vision</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>hunger</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>headache</item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>change in mood</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="Bold">Joint pain.</content> Some people who take medicines called DPP-4 inhibitors like alogliptin tablets, may develop joint pain that can be severe. Call your doctor if you have severe joint pain.</item>
                                 <item>
                                    <content styleCode="Bold">Skin reaction</content>. Some people who take medicines called DPP-4 inhibitors, like alogliptin tablets, may develop a skin reaction called bullous pemphigoid that can require treatment in a hospital. Tell your doctor right away if you develop blisters or the breakdown of the outer layer of your skin (erosion). Your doctor may tell you to stop taking alogliptin tablets.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">The most common side effects of alogliptin tablets include </content>stuffy or runny nose and sore throat, headache, or cold-like symptoms (upper respiratory tract infection).</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Tell your doctor if you have any side effect that bothers you or that does not go away.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">These are not all the possible side effects of alogliptin tablets. For more information, ask your doctor or pharmacist.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">How should I store alogliptin tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Store alogliptin tablets at room temperature between 68°F to 77°F (20°C to 25°C).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">Keep alogliptin tablets and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">General information about the safe and effective use of alogliptin tablets.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not take alogliptin tablets for a condition for which it was not prescribed. Do not give alogliptin tablets to other people, even if they have the same symptoms you have. It may harm them.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">This Medication Guide summarizes the most important information about alogliptin tablets. If you would like to know more information, talk with your doctor. You can ask your doctor or pharmacist for information about alogliptin tablets that is written for health professionals. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">For more information go to <linkHtml href="www.padagis.com">www.padagis.com</linkHtml> or call 1-877-TAKEDA-7 (1-877-825-3327).</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="Bold">What are the ingredients in alogliptin tablets?</content>
                              <br/>
                              <content styleCode="Bold">Active ingredient: </content>alogliptin<br/>
                              <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, hydroxypropyl cellulose, mannitol, and microcrystalline cellulose. In addition, the film-coating contains the following inactive ingredients: ferric oxide (red or yellow), hypromellose, polyethylene glycol and titanium dioxide is marked with printing ink (Gray F1).</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <renderMultiMedia referencedObject="MM6"/>
										Manufactured for Padagis<sup>®</sup>, Minneapolis, MN 55427 • www.padagis.com</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM8"/> and PADAGIS are registered trademarks of Padagis US LLC.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>logo1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_840f0627-d302-4e24-afed-5314e2e1c891">
               <id root="2deeffde-ccc7-4828-b68e-9b260d184b8a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 6.25 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 45802-<content styleCode="bold">087</content>-65<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Alogliptin<br/>Tablets<br/>6.25 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DISPENSE WITH<br/>MEDICATION GUIDE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Padagis<sub>®</sub>
                     </content>
                  </paragraph>
                  <renderMultiMedia ID="id2879" referencedObject="A28D403F-B029-494B-914C-6277B6F2C0AA"/>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="A28D403F-B029-494B-914C-6277B6F2C0AA">
                     <text>PRINCIPAL DISPLAY PANEL - 6.25 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="alogliptin-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_29e00c13-5989-4464-9bfa-2d1328e4ac62">
               <id root="c32e7599-25c2-48ed-bec6-12f80437f569"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 12.5 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 45802-<content styleCode="bold">103</content>-65<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Alogliptin<br/>Tablets <br/>12.5 mg </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DISPENSE WITH<br/>MEDICATION GUIDE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Padagis<sub>®</sub>
                     </content>
                  </paragraph>
                  <renderMultiMedia ID="id2909" referencedObject="BD72C1B4-5BB9-4369-B4FB-2E1092D148C7"/>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="BD72C1B4-5BB9-4369-B4FB-2E1092D148C7">
                     <text>PRINCIPAL DISPLAY PANEL - 12.5 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="alogliptin-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f23cd981-cdfc-42c3-ab4b-74b352c7e66f">
               <id root="f047eaea-0853-4031-9506-0c5b258b630a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 45802-<content styleCode="bold">150</content>-65<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Alogliptin <br/>Tablets <br/>25 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DISPENSE WITH<br/>MEDICATION GUIDE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Padagis<sub>®</sub>
                     </content>
                  </paragraph>
                  <renderMultiMedia ID="id2939" referencedObject="E85B3510-662B-49E9-8691-B9E09399238B"/>
               </text>
               <effectiveTime value="20250411"/>
               <component>
                  <observationMedia ID="E85B3510-662B-49E9-8691-B9E09399238B">
                     <text>PRINCIPAL DISPLAY PANEL - 25 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="alogliptin-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>